Terje R Pedersen
Affiliation: University of Oslo
- High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialTerje R Pedersen
Centre for Preventive Medicine, Ulleval University Hospital, Oslo, Norway
JAMA 294:2437-45. 2005..Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied clinically will provide further benefit in stable coronary artery disease...
- The Success Story of LDL Cholesterol LoweringTerje R Pedersen
From the Oslo University Hospital, Ulleval, Center For Preventive Medicine and University of Oslo, Institute for Clinical Medicine, Oslo, Norway
Circ Res 118:721-31. 2016....
- Intensive lipid-lowering therapy for patients with aortic stenosisTerje R Pedersen
Centre for Preventive Medicine, Ulleval University Hospital, Oslo, Norway
Am J Cardiol 102:1571-6. 2008..In conclusion, the SEAS and ASTRONOMER studies will help resolve the contradictory findings of SALTIRE and RAAVE on the benefit of intensive lipid-lowering treatment in aortic stenosis...
- Lipid-lowering drugs and risk for cancerTerje R Pedersen
Center for Preventive Medicine, Oslo University Hospital, Oslo, Norway
Curr Atheroscler Rep 11:350-7. 2009..Whether statins and other lipid-lowering drugs will increase the risk of cancer when used over several decades is at present unknown...
- Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)Terje R Pedersen
Center for Preventive Medicine, Oslo University Hospital, and University of Oslo, Norway
Am J Cardiol 106:354-9. 2010..The 2 treatment regimens were well tolerated. In conclusion, our analysis provides support for the strategy of placing patients with recent MI on intensive statin therapy and maintaining the high dose over the long term, beyond 2 years...
- Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol loweringTerje R Pedersen
Centre for Preventative Medicine, Ulleval University Hospital, University of Oslo, Oslo, Norway
Am J Cardiovasc Drugs 10:10-7. 2010..Future cholesterol-lowering modalities must be able to demonstrate efficacy and good tolerability in large-scale clinical trials...
- Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL studyIngar Holme
Center of Preventive Medicine, Oslo University Hospital, Sector Ullevål, Oslo, Norway
Eur J Cardiovasc Prev Rehabil 16:315-20. 2009..78-1.01) using atorvastatin 80 mg versus simvastatin 20-40 mg in patients with coronary heart disease (P=0.07). Adherence was high in both treatment groups but significantly higher in patients treated with simvastatin...
- Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL)Ingar Holme
Center of Preventive Medicine, Ulleval University Hospital, Oslo, Norway
Ann Med 40:456-64. 2008..Few studies have looked into the ability of measurements of apolipoprotein B (apoB) and apolipoprotein A-1 (apoA-1) or apoB/apoA-1 to predict new coronary heart disease (CHD) events in patients with CHD on statin treatment...
- Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL)Ingar Holme
Centre of Preventive Medicine, Ulleval University Hospital, Oslo, Norway
Atherosclerosis 205:522-7. 2009..Very few, if any, studies have assessed the ability of apolipoproteins to predict new-onset of congestive heart failure (HF) in statin-treated patients with coronary heart disease (CHD)...
- Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering studyTerje R Pedersen
Center for Preventive Medicine, Ulleval University Hospital, N 0407 Oslo, Norway
Am J Cardiol 94:720-4. 2004..2 +/- 0.3 mmol/L (46 mg/dl). Drug treatment before randomization consisted of statins in 77% of patients, aspirin in 78.9%, beta blockers in 75.1%, and angiotensin-converting enzyme inhibitors in 30%...
- Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trialIngar Holme
Centre of Preventive Medicine, Oslo University Hospital, Ulleval, Oslo, Norway
Am J Cardiol 105:1802-8. 2010....
- Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery diseaseTorgun Waehre
Research Institute of Internal Medicine, Department of Cardiology, Rikshospitalet University Hospital, Oslo, Norway
J Am Coll Cardiol 41:1460-7. 2003..We sought to investigate whether the activation of the chemokine network observed in patients with coronary artery disease (CAD) could be modified by treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)...
- A risk score for predicting mortality in patients with asymptomatic mild to moderate aortic stenosisIngar Holme
Department of Endocrinology, obesity and preventive medicine, Oslo University Hospital, Ulleval, Oslo, Norway
Heart 98:377-83. 2012..Prognostic information for asymptomatic patients with aortic stenosis (AS) from prospective studies is scarce and there is no risk score available to assess mortality...
- Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinicSilvia Rollefstad
Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Ann Rheum Dis 72:1968-74. 2013..To perform cardiovascular risk stratification in patients with inflammatory joint diseases (IJD) and treat to lipid targets according to recommendations...
- Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint diseaseAnne Grete Semb
Diakonhjemmet Hospital, Oslo, Norway
Arthritis Rheum 64:2836-46. 2012....
- Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) studyAnne B Rossebø
Division of Cardiology, Aker University Hospital, Oslo, Norway
Am J Cardiol 99:970-3. 2007..4+/-0.7 mmol/L (126 mg/dl). The SEAS Study is the largest randomized trial to date in patients with AS and will allow determination of the prognostic value of aggressive lipid lowering in such patients...
- HDL-cholesterol and prediction of coronary heart disease: modified by physical fitness? A 28-year follow-up of apparently healthy menPer Torger Skretteberg
Department of Cardiology, Oslo University Hospital, Ullevaal, Norway
Atherosclerosis 220:250-6. 2012..Increased PF is associated with increased HDL and may partly explain the benefit of HDL. We tested the hypothesis that PF influences the prognostic impact of HDL for CHD and also for CHD-, CVD- and all-cause death...
- Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapyAnne G Semb
Cardiologic Department, Aker Hospital, Oslo, Norway
J Am Coll Cardiol 41:275-9. 2003..In the present study, we investigated the effects of statins on serum levels of soluble CD40 ligand (sCD40L) in patients with familial hypercholesterolemia (FH)...
- Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention studyEirik Ikdahl
Preventive Cardio Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, P O Box 23, Vinderen, 0319, Oslo, Norway
Arthritis Res Ther 17:279. 2015..Furthermore, to evaluate correlations between change in FMD (ΔFMD) and change in carotid plaque (CP) height, arterial stiffness [aortic pulse wave velocity (aPWV) and augmentation index (AIx)], lipids, disease activity and inflammation...
- Simvastatin: a reviewTerje R Pedersen
Centre for Preventive Medicine, Ulleval University Hospital, Oslo, Norway
Expert Opin Pharmacother 5:2583-96. 2004..Because of its long record of safety and demonstrated ability to reduce cardiovascular risk, simvastatin has recently become available without a prescription in the UK at the 10 mg dosage level...
- Left ventricular systolic and diastolic function in asymptomatic patients with moderate aortic stenosisKjetil Steine
Aker University Hospital, Oslo, Norway
Am J Cardiol 102:897-901. 2008..Augmented LV filling pressure measured by E/E'sep and impaired LV relaxation measured by reduced E'sep also indicate diastolic dysfunction in these patients...
- Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year ResultsKarina Berg
Department of Ophthalmology, Oslo University Hospital, Oslo, Norway Electronic address
Ophthalmology 123:51-9. 2016..Hoffmann-La Roche Ltd, Basel, Switzerland) versus ranibizumab (Lucentis; Novartis Pharma AG, Basel, Switzerland) for neovascular age-related macular degeneration (nAMD) after 2 years when using a treat-and-extend protocol...
- Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocolKarina Berg
Department of Ophthalmology, Oslo University Hospital, Oslo, Norway Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
Ophthalmology 122:146-52. 2015..To compare the efficacy and safety of bevacizumab versus ranibizumab when administered according to a treat-and-extend protocol for the treatment of neovascular age-related macular degeneration (AMD)...
- Hyperlipidaemia and aortic valve diseaseAnne Bjørhovde Rossebø
Cardiology Department, Aker University Hospital, Oslo, Norway
Curr Opin Lipidol 15:447-51. 2004..This review addresses the role of the various risk factors and the potential for intervention...
- Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)Kalevi Pyorala
Department of Medicine, Kuopio University Hospital, Kuopio, Finland
Diabetes Care 27:1735-40. 2004....
- Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trialJames A de Lemos
Donald W Reynolds Cardiovascular Clinical Research Center, The University of Texas Southwestern Medical Center, Dallas 75390 9047, USA
JAMA 292:1307-16. 2004..Limited data are available evaluating how the timing and intensity of statin therapy following an acute coronary syndrome (ACS) event affect clinical outcome...
- High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studiesWim A van der Steeg
Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
J Am Coll Cardiol 51:634-42. 2008....
- Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiencyMichel Chonchol
Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, CO 80262, USA
Am J Kidney Dis 49:373-82. 2007..Few studies examined the effects of statins on all-cause mortality and major coronary events in patients with renal dysfunction...
- Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosisAnne B Rossebø
Division of Cardiology, Aker University Hospital, Trondheimsveien 235, N 0514 Oslo, Norway
N Engl J Med 359:1343-56. 2008..Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic valve, but lipid-lowering studies have had conflicting results...
- Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatmentJohn J P Kastelein
Academic Medical Center, Department of Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands
Circulation 117:3002-9. 2008....
- Prevention of cardiovascular ischemic events: high-risk and secondary preventionJacques Genest
Division of Cardiology, McGill University Health Center, Montreal, QC, Canada H3A 1A1
Circulation 107:2059-65. 2003
- Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trialHallvard Holdaas
Lancet 361:2024-31. 2003..We investigated the effects of fluvastatin on cardiac and renal endpoints in this population...
- The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)Cynthia J Girman
Departments of Epidemiology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
Am J Cardiol 93:136-41. 2004..It appears that the metabolic syndrome is associated with risk that is not entirely accounted for by traditional risk scoring paradigms...
- fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT StudyAlan G Jardine
Western Infirmary, Glasgow, Scotland, UK
Am J Transplant 4:988-95. 2004..The subgroups included patients at lower cardiovascular risk, who were younger, nondiabetic, nonsmokers and without pre-existing CVD. These data support the early introduction of statins following renal transplantation...
- Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)Timo E Strandberg
Department of Medicine, University of Helsinki, Helsinki, PL 340, 00029 HUS, Finland
Lancet 364:771-7. 2004..We extended post-trial follow-up of participants in the Scandinavian Simvastatin Survival Study (4S) to investigate cause-specific mortality and incidence of cancer 5 years after closure of the trial...
- Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998Terje R Pedersen
Atheroscler Suppl 5:99-106. 2004
- Viewpoint: Terje R. Pedersen, MD, PhD. Interview by Robert ShortTerje R Pedersen
Circulation 115:f51-2. 2007
- Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol managementAlberico L Catapano
Centre for the Study of Atherosclerosis, Marie Curie Training Centre for Cardiovascular Diseases, University of Milan, Milan, Italy
Eur J Cardiovasc Prev Rehabil 14:340-5. 2007..According to a recent report by the Stockholm Network (an independent European 'think tank'), major political, economic, social, and medical changes are urgently needed with respect to cholesterol management to help prevent CVD...
- Statin therapy: changing the mode of coronary heart diseaseTerje R Pedersen
Cardiology 109:154-5. 2008